GLP-1SG Is Semaglutide: What the Vendor Code Name Actually Means

GLP-1SG is not a compound. It is a catalog code that research-peptide vendors use for semaglutide, the FDA-approved GLP-1 receptor agonist sold on prescription as Ozempic and Wegovy. There is no distinct molecule and no literature.

Everything substantive about the drug — mechanism, the trial record, side effects, regulatory status — is in semaglutide science, weight loss and safety profile, inside the weight loss and metabolic peptides category. This page exists to resolve the name, correct what was claimed under it, and give you the identity test.

Is GLP-1SG a real compound?

No. GLP-1SG is a vendor catalog code for semaglutide, not a molecule of its own: a search of the biomedical databases returns zero records for the term. The vendors using it say so themselves. Their product pages describe GLP-1SG as "the catalog designation for Semaglutide", file it under the URL slug semaglutide-research-peptide, and publish CAS 910463-68-2 and a molecular weight of 4,113.58 g/mol on the same page.

Those are semaglutide's own identifiers, and they verify independently: PubChem CID 56843331, formula C₁₈₇H₂₉₁N₄₅O₅₉, molecular weight 4,113.6. The "SG" is simply semaglutide.

The compound page is semaglutide. The old /peptides/glp-1sg entity has been retired and redirects there.

Why do vendors sell semaglutide under a code name?

Because the real name gets filtered. Payment processors, marketplaces and advertising platforms restrict listings for semaglutide, Ozempic and Wegovy, because those are prescription medicines. A catalog code containing none of those strings passes automated checks that the real name would fail. That is the entire mechanism — the "SG" is simply semaglutide. It is not a research designation, not a next-generation analogue, and not evidence of a novel compound.

Recognising the pattern is a useful skill in this market generally. When a vendor invents a name for something that already has one, the reason is rarely scientific. A genuinely new compound arrives with a development code its sponsor uses in public, a CAS number, and a literature trail. An alias arrives with none of those and a product description instead.

Which GLP-1SG claims are false?

All seven of the claims that circulated about GLP-1SG as a distinct compound are false or meaningless. It is not a GLP-1 / growth-hormone-secretagogue hybrid — semaglutide does not bind GHS-R1a. It has no exendin-4 backbone. The research code "NN9990" appears in no Novo Nordisk material. Its CAS is not pending. It is not preclinical: semaglutide has been FDA-approved since 2017. And the −21.3% primate weight-loss study does not exist.

The last row is the instructive one. A comparison claim between a compound and itself cannot be tested, cannot be false in the ordinary sense, and cannot be corrected by better data — which is exactly the kind of claim a fabricated product description produces.

What does knowing the alias change when you buy?

Three things. You know what the certificate of analysis must show — mass spectrometry near 4,113.6 Da and CAS 910463-68-2 — so a vendor who cannot produce identity data matching semaglutide is either mislabelling or does not know what is in the vial. You know the characteristic failure mode, since semaglutide is one of the most commonly underdosed compounds in the gray market. And you know it is a prescription medicine.

Underdosing is the failure that costs money quietly. A vial can be 99% pure and still contain substantially less peptide than the label claims, because purity and quantity are separate measurements — see why 10 mg isn't 10 mg, and mass spectrometry for peptides for what an identity test actually establishes. The compound-specific walkthrough is where to buy semaglutide: 7 purity and identity checks.

Peptigrity tracks 530 shops and 11,852 independent lab tests across 118 peptides, with 1,283 community reviews (verified August 2026). Trust scores weight community reviews and independently verified HPLC purity equally, at 50% each, with no financial relationship influencing the ranking. Per-compound purity and test counts are read live from the Purity Index, independent results from the lab test database, and per-milligram offers with shops-in-stock, median and lowest price from semaglutide price data. Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing.

Where does the law stand on semaglutide sold as a research chemical?

Semaglutide is a prescription medicine whatever a catalog calls it, and the US route that briefly made non-branded versions widely available has closed. The FDA declared the semaglutide shortage resolved in February 2025, enforcement discretion for compounders ended in April and May 2025, and the agency has proposed permanently excluding semaglutide from the 503B bulks list. Calling a vial "research use only" does not change its regulatory classification.

That sequence is also why alias listings proliferated. While compounded semaglutide was widely available, there was less commercial pressure to route around the name; once the pathway closed, the demand did not, and a catalog code became the workaround. See can you get semaglutide without a prescription and our FDA peptide regulation timeline.

Which other peptide names work the same way?

Alias-based listing is common, and semaglutide is not the only compound with one. Vendors seed alternate designations for compounds whose real names attract scrutiny or which are commonly confused: pentadeca arginate for BPC-157 analogues, Mod GRF 1-29 for CJC-1295 without DAC, acetyl hexapeptide-8 for Argireline, and brand names such as Foundayo for orforglipron. The rule that survives all of them is to check the CAS number and the mass, not the name.

Names are marketing; identifiers are chemistry. Our peptide glossary covers the terminology, and oral GLP-1 orforglipron vs injectable peptides covers the newest entry on that list.

The trial that would settle this

No clinical trial can settle what GLP-1SG is, because it is a label rather than a molecule — semaglutide's trial record already answers every pharmacological question. The open question is analytical, not clinical: how far the contents of vials sold as GLP-1SG diverge from the label. Settling it needs a blinded purchase-and-assay study across vendors, measuring identity, purity and net peptide content on every batch.

Until that study exists, treat the alias as a signal rather than a specification. A vendor willing to rename a prescription medicine to get it past a payment filter has already told you how it handles the parts of the process you cannot see.

Frequently Asked Questions

Is GLP-1SG the same as semaglutide?

Yes. It is a vendor catalog code for semaglutide, confirmed on the storefronts that use it — several of which publish semaglutide's own CAS number and molecular weight on the same product page. There is no chemical difference because there is no separate chemical.

Is GLP-1SG a new or experimental peptide?

No. Searches of the biomedical literature return zero records for the term. There is no research programme, no trial, and no distinct molecule — only a catalog entry for a drug that has been approved since 2017.

Is it legal to buy?

Semaglutide is a prescription medicine. Buying it as an unapproved "research" product does not change its legal classification, and the compounding pathway that once supplied non-branded semaglutide has been closed since 2025.

How do I check what's actually in the vial?

Ask for a batch-matched certificate of analysis with mass spectrometry identity — expect a mass near 4,113.6 Da — and a net peptide content figure alongside HPLC purity. Purity alone tells you nothing about identity or quantity, which are the two things that go wrong.

Does GLP-1SG preserve muscle better than semaglutide?

The question cannot be answered because it is semaglutide. The premise is also wrong: in the STEP 1 DXA substudy, lean mass rose as a proportion of total body mass by 3.0 percentage points.

Why did this article change?

An earlier version described GLP-1SG as a novel dual-action Novo Nordisk compound with primate trial data. No such compound exists, and every citation supporting that description was found to be dead or mis-targeted during an August 2026 audit. The article has been rewritten to say what the name actually refers to.

If you arrived looking for information about the compound itself, the substantive coverage is in semaglutide science, weight loss and safety profile — mechanism, the STEP and SELECT trial record, side effects, and current regulatory status.

Browse the weight loss and metabolic peptides category, or our complete peptide guide with 118 compounds (verified August 2026). For reconstitution and per-injection volume, use the semaglutide calculator alongside the reconstitution calculator. Compare shops through independent lab tests and community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.